English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Pretreatment serum levels of interferon-γ-inducible protein-10 (IP-10, CXCL10) and dipeptidyl peptidase-4 (DPP IV) predict treatment response in chronic hepatitis C (CHC). The association between functional genetic polymorphisms of  CXCL10  and  DPP4  and treatment outcome has not previously been studied. This study aimed to determine the association between genetic variations of  CXCL10  and  DPP4  and the outcome of treatment with pegylated interferon-α (PEG-IFN-α) based therapy in Thai patients with CHC. 602 Thai patients with CHC treated using a PEG-IFN-α based regimen were genotyped for  CXCL10  rs56061981 G>A and  IL28B  rs12979860 C>T. In addition, in patients infected with CHC genotype 1,  DPP4  (rs13015258 A>C, rs17848916 T>C, rs41268649 G>A, and rs 17574 T>C) were genotyped. Correlations between single nucleotide polymorphisms, genotype, and treatment response were analyzed. The rate of sustained virologic response (SVR) was higher for the CC genotype of  IL28B  rs12979860 polymorphisms than for non-CC in both genotype 1 (60.6% vs. 29.4%,  P  < 0.001) and non-genotype 1 (69.4% vs. 49.1%,  P  < 0.05) CHC. SVR was not associated with the  CXCL10  gene variant in all viral genotypes or  DPP4  gene polymorphisms in viral genotype1. Multivariate analysis revealed  IL28B  rs12979860 CC genotype (OR = 3.12; 95% CI, 1.72–5.67;  P  < 0.001), hepatitis C virus RNA < 400,000 IU/ml (OR = 2.21; 95% CI, 1.22–3.99,  P  < 0.05), age < 45 years (OR = 2.03; 95% CI, 1.11–3.68;  P  < 0.05), and liver fibrosis stage 0–1 (OR = 1.64; 95% CI, 1.01–2.65,  P  < 0.05) were independent factors for SVR. Unfavorable  IL28B  rs12979860 CT or TT genotypes with the  CXCL10  rs56061981 non-GG genotype were associated with a higher SVR than GG genotype (66.7% vs. 33.0%,  P  = 0.004) in viral genotype 1. In Thai CHC genotype 1 infected patients with an unfavorable  IL28B  rs12979860 CT/TT genotype, the complementary  CXCL10  polymorphism strongly enhances prediction of treatment response.

plos one

Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection